219 related articles for article (PubMed ID: 30712236)
1. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Wang Y; Li S; Zhu L; Zou J; Jiang X; Chen M; Chen B
Clin Transl Oncol; 2019 Aug; 21(8):1026-1033. PubMed ID: 30712236
[TBL] [Abstract][Full Text] [Related]
2. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
3. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression.
Chen B; Zhang Y; Wang Y; Rao J; Jiang X; Xu Z
J Steroid Biochem Mol Biol; 2014 Sep; 143():11-8. PubMed ID: 24486718
[TBL] [Abstract][Full Text] [Related]
4. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Chen HY; Liu ZH
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
[TBL] [Abstract][Full Text] [Related]
7. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 17beta-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78.
Wang XQ; Aka JA; Li T; Xu D; Doillon CJ; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():188-197. PubMed ID: 28645527
[TBL] [Abstract][Full Text] [Related]
9. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
10. YY1 suppresses FEN1 over-expression and drug resistance in breast cancer.
Wang J; Zhou L; Li Z; Zhang T; Liu W; Liu Z; Yuan YC; Su F; Xu L; Wang Y; Zhou X; Xu H; Hua Y; Wang YJ; Zheng L; Teng YE; Shen B
BMC Cancer; 2015 Feb; 15():50. PubMed ID: 25885449
[TBL] [Abstract][Full Text] [Related]
11. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression.
He L; Zhang Y; Sun H; Jiang F; Yang H; Wu H; Zhou T; Hu S; Kathera CS; Wang X; Chen H; Li H; Shen B; Zhu Y; Guo Z
EBioMedicine; 2016 Dec; 14():32-43. PubMed ID: 27852524
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
15. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
He L; Luo L; Zhu H; Yang H; Zhang Y; Wu H; Sun H; Jiang F; Kathera CS; Liu L; Zhuang Z; Chen H; Pan F; Hu Z; Zhang J; Guo Z
Mol Oncol; 2017 Jun; 11(6):640-654. PubMed ID: 28371273
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
[TBL] [Abstract][Full Text] [Related]
17. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
[TBL] [Abstract][Full Text] [Related]
18. Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression.
Zou J; Zhu L; Jiang X; Wang Y; Wang Y; Wang X; Chen B
Oncotarget; 2018 Feb; 9(13):11268-11278. PubMed ID: 29541412
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
20. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
